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SUMMARY. The study was undertaken to investigate the
features and clinical implications of hepatitis B virus (HBV)
genotypes, basal core promoter (BCP) and precore (PC)
mutations in hepatitis B-related acute-on-chronic liver fail-
ure (HB-ACLF). Samples from 75 patients with HB-ACLF and
without pre-existing liver cirrhosis and 328 age-matched
patients with chronic hepatitis B (CHB) were analyzed. HBV
genotype and BCP/PC mutations were determined by direct
sequencing. Mutations at 8 sites of the BCP/PC region were
compared between the two groups of patients. A signiﬁ-
cantly higher ratio of genotype B to C was found in patients
with HB-ACLF than in patients with CHB (30.7–69.3%
vs16.5–82.6%, P < 0.01). Single mutations including
T1753V (C/A/G), A1762T, G1764A, G1896A and G1899A
and triple mutations T1753V/A1762T/G1764A and
A1762T/G1764A/C1766T(orT1768A)weremorefrequently
detected in patients with HB-ACLF than in patients with
CHB. Correspondingly, BCP/PC wild-type sequences were
absent in patients with HB-ACLF in contrast to 27.1% in
patients with CHB. The BCP/PC mutations were found to be
associated with increased HBeAg negativity, higher alanine
aminotransferase level and lower viral load. Patients with
HB-ACLF infected with the PC mutant virus had a higher
mortality. The ﬁndings suggest that patients with CHB
infected with genotype B with BCP/PC mutations were more
likely to develop HB-ACLF than those with genotype C with
wild-type BCP/PC regions, and patients with HB-ACLF with
the PC mutation had increased risk of a fatal outcome.
Keywords: acute-on-chronicliverfailure,basalcorepromoter,
hepatitis B virus, mutation, precore.
INTRODUCTION
Hepatitis B virus (HBV) is responsible for chronic infection
in about 350 million people worldwide and 93 million of
them are in China [1,2]. Chronic HBV infection leads to a
wide spectrum of clinical presentations ranging from an
asymptomatic carrier state to chronic hepatitis B (CHB)
with progression to liver cirrhosis (LC) and hepatocellular
carcinoma (HCC) or to acute-on-chronic liver failure
(ACLF). Recommendations for the deﬁnition of ACLF by
the Asian Paciﬁc Association for the Study of the Liver
include acute hepatic insult characterized by jaundice and
coagulopathy, complicated within 4 weeks by ascites and/
or encephalopathy in a patient with previously diagnosed
or undiagnosed chronic liver disease [3]. Similarly, in
China, ACLF is deﬁned as acute liver decompensation
on the basis of chronic liver disease with mandatory
jaundice [serum total bilirubin (TBIL) >171.0 lmol/L (i.e.
>10.0 mg/dL) or a rapid rise >17.1 lmol/L/day (i.e.
>1.0 mg/dL/day)] and coagulopathy [plasma prothrombin
activity (PTA) <40%] and recent development of compli-
cations [4]. Different from western countries where alco-
holic cirrhosis constitutes 50–70% of all underlying liver
diseases in China, hepatitis B-related ACLF (HB-ACLF)
cases account for more than 80% of ACLF cases as a
result of the high incidence of chronic HBV infection
[4,5]. HB-ACLF is reported to have a high mortality rate
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  2010 Blackwell Publishing Ltd(60–80%) in the absence of liver transplantation, causing
22 600 deaths annually [6].
The pathogenesis of HB-ACLF remains largely unclear.
Both viral and host factors may play a role. HBV is classiﬁed
into eight genotypes (A–H) that may vary in geographical
distribution, viral characteristics and relationship to clinical
outcomes. HBV mutations in the basal core promoter (BCP)
and precore (PC) have attracted special attention, because
the BCP mutations may enhance HBV replication in vitro
and the PC mutation abrogates translation of HBeAg, which
is considered a tolerogen buffering any immune attack on
the infected hepatocytes [7–9]. Studies have been performed
to clarify these virologic features in patients with acute liver
failure (ALF) who developed fulminant hepatitis from acute
HBV infection. A higher prevalence of the BCP double
mutation A1762T/G1764A and the G1896A PC mutation
have been reported in ALF than in acute hepatitis B patients
[10–15]. In addition, single mutations including the
T1753V (C/A/G), C1766T, T1768A, G1862T and G1899A
in the BCP/PC region have been reported to be associated
with increased HBV replication capacity and/or reduced
HBeAg expression in vitro, and in some cases associated with
ALF in the clinic [7,15–19]. The inﬂuence of HBV genotypes
on ALF has also been reported. Ozasa et al. [14] reported that
patients infected with HBV/Bj were more likely to develop
ALF compared to patients with HBV/Ae. However, incon-
sistent ﬁndings exist, showing no obvious link between HBV
BCP/PC mutations and ALF or fulminant hepatitis develop-
ment [20–23]. In some of these studies, a small sample size
was used and genotypes were not deﬁned. Bias therefore
may partly account for the discrepancies in the conclusions
from individual investigations.
Until now, little is known about the association of HBV
genotypes and BCP/PC mutations with HB-ACLF develop-
ment. Liu et al. [24] reported that these virologic features
seemed not to associate with the fulminant exacerbation of
CHB using a small sample size. Considering that the BCP/PC
mutation prevalence may increase in LC patients [25,26],
and older age is often associated with longer disease duration
as persistent HBV infection is established mainly during in-
fancy in most Asian countries [27], we analyzed viral
genotype/subgenotype and BCP/PC mutations in a large
number of patients with HB-ACLF and without pre-existing
LC and age-matched patients with CHB in this study.
PATIENTS AND METHODS
Patients
Sera from 559 patients with HB-ACLF who were admitted to
the Beijing 302 Hospital from January 2005 to December
2008 were tested. The patients came from various areas of
China, but mainly from the North. Viral genes were suc-
cessfully ampliﬁed and sequenced from both the BCP/PC and
S regions from the sera of 298 cases. As most of these
patients had pre-existing liver cirrhosis and thus were
excluded, only 75 patients with HB-ACLF and without
pre-existing LC were ﬁnally enroled. Three hundred and
twenty-eight age-matched patients with CHB were taken as
controls. The diagnostic criteria were based on the 2000
Xian viral hepatitis management scheme issued by the
Chinese Society of Infectious Diseases and Parasitology, and
the Chinese Society of Hepatology from the Chinese Medical
Association [28]. All patients were seroposite for HBsAg for
at least 6 months before enrolment. Patients with HB-ACLF
met the following criteria: recent development of jaundice
[TBIL >171.0 lmol/L (i.e. >10.0 mg/dL) or rapidly rising
levels of >17.1 lmol/L/day (i.e. >1.0 mg/dL/day)] and
decreasing PTA (<40%), with development of complications
such as hepatic encephalopathy (‡grade 2), or abrupt and
obvious increase in ascites or spontaneous bacterial perito-
nitis or hepatorenal syndrome. Patients with CHB met the
following criteria: a history of chronic hepatitis based on
histopathological diagnosis and/or compatible laboratory
data and ultrasonographic ﬁndings, with mild to moderate
liver inﬂammatory manifestations. For all patients, there was
no evidence for LC, HCC or other metastatic liver disease; no
evidence for concomitant HCV, HDV or HIV infection or
autoimmune liver disease. Sera from patients with HB-ACLF
were sampled once the diagnosis was made. The study was
approved by the ethics committee of the Beijing 302
Hospital.
Serological markers and quantiﬁcation of hepatitis B virus
DNA
Serum alanine aminotransferase (ALT), TBIL, albumin and
other biochemical parameters were measured by standard
procedures. HBeAg/anti-HBe, HBsAg/anti-HBs and anti-HBc
were detected by enzyme-linked immunosorbent (Kewei
Diagnostic Ltd., Beijing, China) or chemiluminescent assays
(Abbott Laboratories, Chicago, IL, USA). HBV DNA level was
determined by a real-time PCR kit (Fuxing Clone Co.,
Shanghai, China) with a lower limit of detection of
500 copies/mL (about 100 IU/mL).
Detection of the basal core promoter/precore mutations
Viral DNA was extracted from 140 lL of serum using a Viral
DNAout kit (Tiandz Engineering, Beijing, China). HBV gen-
ome sequences were determined by direct sequencing after
PCR ampliﬁcation. Primers for ampliﬁcation of the BCP and
PC regions were as follows: 5¢-GAC GTC CTT TGT YTA CGT
CC-3¢ (nt 1413–1432) and 5¢-TCT GCG ACG CGG CGA TTG
AG-3¢(antisense, nt 2403–2422) for the ﬁrst-round PCR;
5¢-ACT TCG CTT CAC CTC TGC AC-3¢(sense, nt 1583–1602)
and 5¢-ATC CAC ACT CCA AAA GAY ACC-3¢(antisense, nt
2257–2277) for the second-round PCR. The ﬁrst-round PCR
consisted of equilibrating at 94  C for 3 min; 10 cycles at
94  C for 35 s, 59  C for 35 s (decreasing by 2  C every
  2010 Blackwell Publishing Ltd
888 X. Ren et al.other cycle), 72  C for 70 s; and 30 cycles at 94  C for 35 s,
56  C for 35 s, and 72  C for 70 s. The second-round PCR
entailed a denaturation step at 94  C for 3 min and 35
cycles at 94  C for 25 s, 56  C for 25 s and 72  C for 50 s.
The PCR products were separated on 1% agarose gels and
puriﬁed by gel recovery. Sequencing was performed using an
ABI 3730xl DNA Analyzer (Applied Biosystems, Foster City,
CA, USA). Analysis and assembly of sequencing data were
performed with the Vector NTI Suite software package
(Informax, Frederick, MD, USA).
Typing of hepatitis B virus genotypes/subgenotypes
The genotyping was based on S-gene sequences encom-
passing the reverse-transcriptase domain of HBV, which was
ampliﬁed by an in-house nested PCR assay as previously
described [2]. The entire 1225-bp fragments (nt 54–1278)
ampliﬁed were directly sequenced. HBV genotype and sub-
genotype were determined by molecular evolutionary anal-
ysis of the viral sequences using the MEGA 4 software.
Phylogenetic trees were constructed using neighbour-joining
(NJ) analysis with bootstrap test conﬁrmation performed on
1000 resamplings. Standard reference sequences were
acquired from the online Hepatitis Virus Database (http://
www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi)
as previously reported [29].
Statistical analysis
Values for results were expressed as means ± standard
deviation or median. Differences in data between two groups
were examined by chi-square test, Fishers exact test,
Students t-test or nonparametric Mann–Whitney U test
where appropriate. Statistical analysis was carried out in
SPSS 16.0 software. A P value of <0.05 was considered
statistically signiﬁcant.
RESULTS
Clinical background, hepatitis B virus genotype/
subgenotype and basal core promoter/precore mutation
proﬁles of the studied patients
Table 1 summarizes the clinical background and the viro-
logic characteristics (HBV genotypes, BCP/PC mutations) of
the 75 HB-ACLF and 328 patients with CHB. Genotype B
(B1, 2.6%; B2, 92.2%; B3, 1.3%; B4, 1.3%; undetermined,
2.6%), C (C1, 1.6%; C2, 96.6%; C3, 1.2%; C4, 0.3%; unde-
termined, 0.3%) and D were detected in 19.1%, 80.1% and
0.8% of patients, respectively. A signiﬁcantly higher ratio of
genotype B to C was found in HB-ACLF than in patients with
CHB (30.7–69.3% vs 16.5–82.6%, P < 0.01). Alternatively,
29.9% (23/77) of the patients with genotype B virus
Table 1 Clinical background, HBV genotype and BCP/PC mutation proﬁles of the patients studied
Total (n = 403) HB-ACLF (n = 75) CHB (n = 328) P value
Gender (M/F) 348/55 67/8 281/47 0.405
Age (years) 39 (18–75) 39 (19–72) 38 (18–75) 0.273
Total bilirubin (lmol/L) 15.3 (3.8–1053) 451.0 (191.1–1053) 12.8 (3.8–77) <0.001
ALT (IU/L) 50 (7–3774) 569 (57–3774) 41(7–665) <0.001
HBV DNA (logcps/mL) 5.26 ± 1.6 5.3 ± 1.7 5.2 ± 1.6 0.702
Prothrombin activity (%) 75.0 (5.0–238.9) 22.7 (5–42) 87.4 (43.6–238.9) <0.001
Albumin 41.5 ± 7.65 29.9 ± 3.45 44.2 ± 5.52 <0.001
Albumin/globulin ratio 1.58 ± 0.46 1.23 ± 0.64 1.66 ± 0.36 <0.001
HBeAg+ 223 (55.8%) 29 (38.7%) 194 (59.1%) 0.001
Anti-HBe+ 122 (30.3%) 27 (36.0%) 95 (29.0%) 0.231
Genotype B 77 (19.1%) 23 (30.7%) 54 (16.5%) 0.009
Genotype C 323 (80.1%) 52 (69.3%) 271 (82.6%) 0.009
Genotype D 3 (0.8%) 0 3 (0.9%) –
Wild type 89 (22.1%) 0 89 (27.1%) <0.001
T1753V (C/A/G) 72 (17.9%) 21 (28%) 51 (15.5%) 0.012
T1754G 11 (2.7%) 3 (4.0%) 8 (2.4%) 0.193
A1762T 230 (57.1%) 58 (77.3%) 172 (52.4%) <0.001
G1764A 239 (59.3%) 62 (82.7%) 177 (54.0%) <0.001
C1766T 21 (5.2%) 5 (6.7%) 16 (4.9%) 0.529
T1768A 10 (2.5%) 2 (2.7%) 8 (2.4%) 0.584
G1896A 138 (34.2%) 34 (45.3%) 105 (32.0%) 0.038
G1899A 34 (8.4%) 12 (16.0%) 22 (6.7%) 0.013
HB-ACLF, hepatitis B-related acute-on-chronic liver failure; ALT, alanine aminotransferase; BCP, basal core promoter; CHB,
chronic hepatitis B; HBV, hepatitis B virus; PC, precore.
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patients with genotype C infection. A signiﬁcantly higher
prevalence of the T1753V, A1762T, G1764A, G1896A and
G1899A mutations was detected in HB-ACLF than in
patients with CHB. Wild-type BCP/PC sequences (at the 8
mutation sites analyzed) were found in none of the patients
with HB-ACLF, but such sequences were present in 27.1% of
patients with CHB.
Individual proﬁles of basal core promoter/precore
mutations in patients infected with genotypes B and C
Genotype B had a signiﬁcantly lower prevalence of BCP
mutations T1753V, A1762T and G1764A but signiﬁcantly
higher prevalence of the G1896A PC mutation in compari-
son with genotype C. The C1766T and T1768A mutations
were not found in the genotype B samples studied. The
average number of substitutions per sample at the eight
analyzed sites was signiﬁcantly higher in genotypes C than B
samples (Table 2).
Table 3 summarizes the proﬁles of the BCP/PC mutations
in patients infected with genotypes B or C separately. In
genotype B infection, a statistical difference in the mutation
occurrence between patients with HB-ACLF and patients
with CHB was only observed at the A1762T and G1764A
sites. By contrast, in genotype C infection, a signiﬁcantly
higher mutation prevalence was observed at the 1753,
1762, 1764, 1896 and 1899 sites in patients with HB-ACLF
in comparison with patients with CHB. Nevertheless, the
average number of substitutions per sample was signiﬁcantly
higher in HB-ACLF than in patients with CHB for both
genotypes B and C infections.
Hepatitis B virus basal core promoter/precore mutational
patterns and disease status
To simplify data analysis, we deﬁned the A1762T/G1764A
and G1896A as the basic BCP and basic PC mutation,
respectively, as these were well-known hotspot mutations.
Accordingly, there were four basic patterns, i.e. no muta-
tions (BCP)/PC)), BCP mutation only (BCP+/PC)), PC
mutation only (BCP)/PC+) and both mutations (BCP+/
PC+). In addition, the latter two patterns were also analyzed
together as BCP±/PC+. A signiﬁcantly lower frequency of
the BCP)/PC) pattern and a higher frequency of the BCP+/
PC) and BCP±/PC+ patterns were found in patients with
HB-ACLF in comparison with patients with CHB. In addition,
two interesting triple BCP mutations [T1753V/A1762T/
G1764A and A1762T/G1764A/C1766T (or T1768A)] were
more frequently detected in HB-ACLF than in patients with
CHB (Table 4).
Table 2 Comparison of the BCP/PC mutation occurrence
between genotypes B and C
Genotype B
(n = 77)
Genotype C
(n = 323) P value
T1753V 4 (5%) 68 (21.1%) <0.001
T1754G 5 (6%) 6 (2%) 0.025
A1762T 29 (37.7%) 201 (62.2%) <0.001
G1764A 29 (37.7%) 210 (65.0%) <0.001
C1766T 0 21 (6.5%) –
T1768A 0 10 (3.1%) –
G1896A 36 (46.7%) 102 (31.6%) 0.012
G1899A 7 (9%) 27 (8.4%) 0.836
Substitution/
sample*
1.48 2.06 0.001
BCP, basal core promoter; PC, precore. *Represents average
number of substitutions at the eight analyzed sites from the
BCP/PC regions.
Table 3 Individual proﬁles of BCP/PC mutations in patients
infected with genotypes B and C
HB-ACLF
(n = 75)
CHB
(n = 328) P value
Genotype B (n = 77)
Patient number 23 54
Wild type 0 21 <0.001
T1753V 2 (8.7%) 2 (3.7%) 0.366
T1754G 2 (8.7%) 3 (5.6%) 0.714
A1762T 14 (60.9%) 15 (27.8%) 0.006
G1764A 14 (60.9%) 15 (27.8%) 0.006
C1766T 0 0 –
T1768A 0 0 –
G1896A 13 (56.5%) 23 (42.6%) 0.262
G1899A 3 (13.0%) 4 (7.4%) 0.431
Substitution/
sample*
2.17 1.19 <0.001
Genotype C (n = 323)
Patient number 52 271
Wild type 0 68 <0.001
T1753C/A/G 19 (36.5%) 49 (18.1%) <0.001
T1754C/G 1 (1.9%) 5 (1.8%) 0.654
A1762T 44 (84.6%) 157 (57.9%) <0.001
G1764A 48 (92.3%) 162 (59.8%) <0.001
C1766T 5 (9.6%) 16 (5.9%) 0.320
T1768A 2 (3.8%) 8 (3.0%) 0.733
G1896A 20 (38.5%) 82 (30.3%) 0.049
G1899A 9 (17.3%) 18 (6.6%) 0.002
Substitution/
sample*
2.92 1.88 <0.001
HB-ACLF, hepatitis B-related acute-on-chronic liver failure;
BCP, basal core promoter; CHB, chronic hepatitis B; PC,
precore. *Represents the average number of substitutions at
the eight analyzed sites from the BCP/PC regions.
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patterns in relation to alanine aminotransferase and
hepatitis B virus DNA levels, and HBeAg negativity
AsALTlevelwassigniﬁcantlydifferentbetweenHB-ACLFand
CHB groups (Table 1), its association with the basic BCP/PC
patternswasanalyzedseparatelyforthetwogroupsofpatients.
The results showed that ALT was signiﬁcantly higher in both
patientswithHB-ACLFandwithCHBinfectedwiththeBCP+/
PC+ virus than in those with the BCP)/PC) one (Figs 1a,b).
WithrespecttoHBVDNA,astherewasnosigniﬁcantdifference
between HB-ACLF and CHB groups (Table 1), its association
with the basic BCP/PC patterns was analyzed together for the
two groups of patients. The results showed that patients with
BCP+/PC+ virus had lower HBV DNA level than those with
BCP)/PC) or BCP+/PC) viruses (Fig. 1c). The HBeAg nega-
tiverateincreasedinastepwisemannerinpatientswithBCP)/
PC) (21.8%), BCP+/PC) (39.8%), BCP)/PC+ (61.5%) and
BCP+/PC+ (68.8%) viruses (Fig. 1d).
The clinical and virologic characteristics in relation to
mortality in patients with hepatitis B-related acute-on-
chronic liver failure
Of the 75 patients with HB-ACLF, 42 had a fatal outcome
and 33 survived more than 6 months after onset of liver
Table 4 HBV BCP/PC patterns distributed in the two groups
of patients
HB-ACLF CHB P value
Basic BCP/PC
mutations*
n =7 5 n = 328
)/) 5 (6.7%) 119(36.2%)<0.001
+/) 37 (49.3%) 104 (31.7%) 0.003
)/+ 12 (16.0%) 41 (12.5%) 0.262
+/+ 21 (28.0%) 64 (19.5%) 0.073
±/+ 33 (44.0%) 105 (32.0%) 0.034
Triple BCP mutations n =5 2 n = 271
T1753V/A1762T/
G1764A
19 (36.5%) 48 (17.7%) 0.002
A1762T/G1764A/
C1766T(orT1768A)
6 (11.5%) 11 (4.1%) 0.027
HB-ACLF, hepatitis B-related acute-on-chronic liver failure;
BCP, basal core promoter; CHB, chronic hepatitis B; HBV,
hepatitis B virus; PC, precore.
*Positivity (+) or negativity ()) of basic BCP and PC muta-
tions was based on the presence or absence of A1762T/
G1764A and G1896A, respectively.
Only genotype C HBV-infected patients were analyzed.
A1762T/G1764A/C1766T (or T1768A) may be concomi-
tant with T1753V.
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Fig. 1 HBV BCP/PC mutational patterns in relation to alanine aminotransferase (ALT) and HBV DNA levels, and HBeAg
negativity. Four patterns (BCP)/PC), BCP+/PC), BCP)/PC+ and BCP+/PC+) were determined based on positivity (+) or
negativity ()) for the BCP double mutation A1762T/G1764A and the G1896A PC mutation. Association of the BCP/PC
patterns with (a) serum ALT level in patients with hepatitis B-related acute-on-chronic liver failure (HB-ACLF); (b) serum ALT
level in patients with chronic hepatitis B (CHB); (c) serum HBV DNA level in all patients; (d) HBeAg negative rate in all
patients. Data are expressed as box plots, in which the horizontal lines illustrate the 25th, 50th and 75th percentiles for ALT
level, and mean ± SD for HBV DNA level and HBeAg negative rate, respectively. *P < 0.05, **P < 0.01. BCP, basal core
promoter; HBV, hepatitis B virus; PC, precore.
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PTA were detected as risk factors, while a high viral load
(‡10
5 copies/mL) was only marginally signiﬁcant as a risk
factor for mortality. In addition, there was a trend that
infection with genotype B was associated with fatal outcome.
Older age (‡40 years old) and HBeAg negativity were not
associated with survival rate (Table 5).
DISCUSSION
The outcome of HBV infection depends on the interplay
between the virus, the hepatocytes and the hosts immune
response. When the balance is disrupted by the emergence of
particular HBV mutants with altered phenotype, the chan-
ged virus–cell relationship might cause hepatocyte necrosis
and lead to the development of fulminant or severe hepatitis
[30]. Thus, the investigation of the virologic features that
may help explain the pathogenesis and give potential indi-
cators of HB-ACLF development may prove useful. HB-ACLF
is different from fulminant hepatitis on the basis of acute
HBV infection. It is also different from acute exacerbation of
CHB, which is deﬁned as clinical symptoms along with an
abrupt rise in serum ALT to a certain level, e.g. above
200 IU/L [31] or 500 IU/L [32], and only a small proportion
of such patients develops fulminant hepatic failure that
meets the criteria of HB-ACLF. Patients with HB-ACLF are
relatively rare compared to the large population of patients
with CHB in China, and usable samples for the analysis were
even fewer because the sensitivity of the BCP/PC ampliﬁca-
tion was obviously reduced as shown here. The Beijing 302
Hospital is one of the largest hospitals for infectious and liver
diseases in China and is well known for the management of
hepatitis B. Patients from various areas of China come to the
hospital-seeking treatment, and this allowed us to collect a
larger sample size representing patients with HB-ACLF.
Our results showed that genotype B infection was more
frequently observed in HB-ACLF than in patients with CHB,
suggesting that patients with CHB infected with genotype B
have a higher risk of developing liver failure than those
infected with genotype C. A signiﬁcantly higher occurrence
of BCP mutations at the 1753, 1762 and 1764 sites, and PC
mutations at the 1896 and 1899 sites were found in patients
with HB-ACLF than in patients with CHB (Table 1), sug-
gesting that accumulation of BCP/PC mutations could be a
potential indicator and probably a contributor to HB-ACLF
development. Further analysis indicated that the BCP
mutations T1753V, A1762T and G1764A were more
frequently detected in genotype C than in genotype B
isolates, whereas the G1896A PC mutation was more
frequently detected in genotype B than in genotype C ones
(Table 2), conﬁrming previous reports [33,34]. In patients
infected with genotype C, a comparable increase in the
frequency of BCP/PC mutations was obtained as for the total
patient sample; whereas in patients infected with genotype
B, a signiﬁcant difference was only observed at the 1762 and
1764 sites in the BCP region. This may be partly because of a
Table 5 The clinical and viral
characteristics in relation to mortality
in patients with hepatitis B-related
acute-on-chronic liver failure
Factors Survival Nonsurvival P value Odds ratio
Basic BCP/PC mutations
)/) 23 –
+/) 21 16 0.028 0.35 (0.14–0.90)
±/+ 10 23 0.026 3.02 (1.1–8.10)
HBeAg
+ 15 23 0.424 1.45 (0.58–3.63)
) 18 19 1
Total bilirubin
<450 lmol/L 21 15 0.016 1
‡450 lmol/L 12 27 3.15 (1.22–8.14)
Prothrombin activity (%)
<23 11 27 0.007 3.60 (1.38–9.41)
‡23 22 15 1
HBV DNA
<10
5 copies/mL 11 6 0.050 1
‡10
5 copies/mL 22 36 3.00 (0.97–9.26)
Genotype
B 7 16 0.092 2.29 (0.81–6.48)
C2 6 2 6 1
Age
<40 years 19 18 0.151 1
‡40 years 14 24 1.81 (0.72–4.55)
BCP, basal core promoter; HBV, hepatitis B virus; PC, precore.
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892 X. Ren et al.lower number of genotype B infected patients enroled and
partly because of particular genetic features of the viral
genotypes. Nevertheless, the average number of substitu-
tions in the BCP/PC region were signiﬁcantly increased in
the HB-ACLF compared to CHB group regardless of virus
genotype, suggesting that accumulation of the BCP/PC
mutations increased the risk of HB-ACLF occurrence in
general.
The A1762T/G1764A and G1896A well-recognized BCP/
PC mutations were deﬁned as basic BCP and PC mutations in
our study. Patients with HB-ACLF had a signiﬁcantly higher
prevalence of basic BCP mutations alone or in combination
with the basic PC mutation in comparison with patients with
CHB. Correspondingly, virus without basic BCP and PC
mutations was much less frequently detected in patients
with HB-ACLF than in patients with CHB (Table 4). It has
been reported that combined A1762T/G1764A mutations
with T1753V, C1766T and/or T1768A may enhance viral
replication in vitro and are associated with ALF and
advanced liver disease [35–37]. Therefore, we analyzed two
triple BCP mutational patterns T1753V/A1762T/G1764A
and A1762T/G1764A/C1766T (or T1768A) in patients
infected with HBV genotype C, as T1753V was detected
infrequently in genotype B and not at all in C1766T and
T1768A. As a result, both BCP triple mutational patterns
were present signiﬁcantly more so in HB-ACLF than in
patients with CHB, irrespective of whether the G1896A PC
mutation was there or not (Table 4). These data may sug-
gest that emergence of the T1753V, C1766T and T1768A
mutations was likely an additional driving factor for the
development of HB-ACLF.
Elevated ALT level was found to be associated with the
emergence of the basic BCP/PC mutations, both in ACLF and
patients with CHB (Figs 1a,b). By contrast, HBV DNA level
was decreased with the emergence of the basic BCP/PC
mutations (Fig. 1c). It might be speculated that the BCP/PC
mutant viruses with enhanced viral replication and reduced/
abrogated HBeAg expression were more likely to activate
immune responses, leading to ALT elevation and viral load
decline in patients with CHB. In cases where the virus-host
balance is interrupted, a robust and out-of-control inﬂam-
matory response is triggered that may lead to extensive
hepatic injury. However, the alternation of ALT and HBV
DNA levels may be inﬂuenced by the use of antiviral treat-
ment and a blood test at a single time-point may give a
biased evaluation of disease activity for some patients with
CHB with ﬂuctuating ALT and HBV DNA levels, although
these inﬂuences were relatively proportional in the larger
sample size of the current study. As expected, the HBeAg
negative rate increased in a stepwise manner along with the
emergence of the basic BCP mutation, PC mutation or both
(Fig. 1d). As mutant viruses frequently coexist with wild-
type viruses, subpopulations comprising <20% of the total
HBV population may be missed by direct sequencing tech-
niques [38]. Thus, the G1896A mutants can sometimes be
detected in HBeAg positive patients if they are present at
higher levels.
With respect to mortality of patients with HB-ACLF in our
study, infection with the BCP/PC mutants was associated
with nonsurvival in addition to biochemical parameters such
as PTA and TBIL levels. In addition, there was a tendency
towards a fatal outcome in patients with HB-ACLF who had
high HBV DNA levels (‡10
5 copies/mL) and genotype B
infection. Intriguingly, emergence of the BCP mutation alone
seemed to have a protective effect on the occurrence of
HB-ACLF. Older age (‡40 years old) was not an independent
factor that was associated with poor outcome. This is not
consistent with some previous results as in the Kings College
and Clichy criteria [39,40]. This could be explained by
differences in aetiology and clinical status of the patients
enroled in different investigations. In our study, exclusion of
ACLF cases with pre-existing LC minimized any inﬂuences
from complex aetiology.
In summary, HBV genotype and BCP/PC mutations were
associated with development of HB-ACLF. Patients with CHB
infectedwithgenotypeBandBCP/PCmutantvirusweremore
prone to develop HB-ACLF than those with genotype C and
BCP/PC wild-type virus. Patients with HB-ACLF and with PC
mutant virus had an increased risk of having a fatal outcome.
Some of these ﬁndings are similar as those found in ALF and
acute hepatitis B patients, suggesting that HBV genotype and
BCP/PC mutations might comparably be involved in the
pathogenesis of fulminant hepatitis on the basis of both acute
and chronic HBV infection. The study represents the ﬁrst step
towards understanding of the virologic factors that may
contribute to the development of HB-ACLF.
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